文献速递类风湿关节炎

高血清CXCL13水平预测ACPA阳性和ACPA阴性早期类风湿关节炎对csDMARDs反应较低

High serum levels of CXCL13 predict lower response to csDMARDs in both ACPA-positive and ACPA-negative early rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

前瞻性队列纳入243例接受甲氨蝶呤达标治疗的早期类风湿关节炎患者,基线CXCL13≥100 pg/ml在ACPA阳性者占53.6%、ACPA阴性者占31.5%。ACPA阳性者中高CXCL13独立预测6个月未缓解及2年内升级二线治疗,ACPA阴性者中高CXCL13预测甲氨蝶呤加量(调整OR 2.69,95%CI 1.35-5.34)。

要点

  • 基线CXCL13≥100 pg/ml在ACPA阳性早期RA占53.6%,ACPA阴性占31.5%。
  • ACPA阳性者高CXCL13独立预测未缓解(调整OR 0.17-0.49)及二线治疗(OR 6.75)。
  • ACPA阴性者高CXCL13预测甲氨蝶呤加量,调整OR 2.69(95%CI 1.35-5.34)。

核心结论

  • 高血清CXCL13水平识别出对一线甲氨蝶呤治疗更难治的RA患者亚组。
  • CXCL13在ACPA阳性和ACPA阴性早期RA中均似乎是预测甲氨蝶呤反应的有前景生物标志物。

研究设计与样本

  • 前瞻性队列研究,纳入243例接受甲氨蝶呤达标治疗的早期RA患者。
  • 基线检测血清CXCL13、ACPA和IgM-RF,2个月后检测CXCL13短期变化。
  • 在总人群及ACPA亚组中分别评估高CXCL13(≥100 pg/ml)与6个月疾病缓解及第2年内升级二线治疗的关联。

主要发现

  • 高CXCL13水平见于53.6%的ACPA阳性患者和31.5%的ACPA阴性患者,与疾病活动度和RF关联极小。
  • 血清CXCL13在2个月后保持稳定。
  • ACPA阳性患者中,高基线CXCL13独立预测未达到缓解及更频繁需要二线治疗,缓解的调整OR范围为0.17-0.49,二线治疗的调整OR为6.75。
  • ACPA阴性高CXCL13患者中,缓解以更高剂量甲氨蝶呤为代价,CXCL13水平预测甲氨蝶呤加量,调整OR(95%CI)为2.69(1.35-5.34)。

关键数值与推荐

  • 高CXCL13定义为≥100 pg/ml。
  • ACPA阳性患者中高CXCL13预测未缓解的调整OR范围为0.17-0.49。
  • ACPA阳性患者中高CXCL13预测二线治疗的调整OR为6.75。
  • ACPA阴性患者中CXCL13预测甲氨蝶呤加量的调整OR(95%CI)为2.69(1.35-5.34)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Increased circulating levels of CXCL13 reflect synovial production and indicate immune dysregulation in patients with RA. Here we tested whether CXCL13 predicts response to first-line treatment with MTX in patients with early RA, independently and in association with ACPA and IgM-RF. METHODS: A prospective cohort of 243 early RA patients undergoing treat-to-target with MTX was evaluated. CXCL13, ACPA and IgM-RF were determined on baseline sera. Short-term variations of CXCL13 were measured after 2 months. The association of high CXCL13 (≥100 pg/ml) with disease remission after 6 months and escalation to second-line therapies within year 2 was evaluated in the total population and in ACPA subgroups separately. RESULTS: High levels of CXCL13 were found in 53.6% of ACPA-positive and 31.5% of ACPA-negative patients, with minimal association with disease activity and RF. Serum CXCL13 remained stable after 2 months. High baseline CXCL13 independently predicted failure to achieve remission and more frequent requirement of second-line treatment in ACPA-positive patients, with adjusted odds ratios (ORs) in the range of 0.17-0.49 for remission and 6.75 for second-line treatment. In ACPA-negative patients with high CXCL13, remission occurred at the expense of higher doses of MTX, and levels of CXCL13 predicted MTX escalations with an adjusted OR (95% CI) of 2.69 (1.35-5.34). CONCLUSIONS: High serum levels of CXCL13 identify a subgroup of RA patients who are more refractory to first-line treatment with MTX. CXCL13 appears a promising biomarker of response to MTX in both ACPA-positive and -negative early RA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. De Stefano L, Bozzalla Cassione E, Sammali Y, et al. High serum levels of CXCL13 predict lower response to csDMARDs in both ACPA-positive and ACPA-negative early rheumatoid arthritis. Rheumatology (Oxford). 2025. PMID: 39468732. doi:10.1093/rheumatology/keae596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。